Predicting Survival



Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer

https://tinyurl.com/4vebw3w8

 

         One of the many unresolved questions about ovarian cancer is; why do some women survive better than others? This study suggests that an objective measurement of the rapidity of response to chemo may provide a guide as to who will do well.

         As part of the standard care for high-grade ovarian cancer, most women have chemotherapy before surgery, known as neoadjuvant therapy (NACT). . The response to NACT is measured by the reduction of the CA125 antigen; this is elevated in about 90% of epithelial ovarian cancers.

         A retrospective trial for 217 patients with ovarian cancer showed that the rate of elimination of CA125 (KELIM) from serum is related to survival. Patients with slow rates of elimination; (KELIM 1 or less) were more likely to be platinum resistant and had worse progress free survival and overall survival.

 



Comments

Popular posts from this blog

An impossible dream?

It’s not just your genotype

Sugar doesn’t feed cancer